(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date 15 January 2004 (15.01.2004)

PCT

(10) International Publication Number WO 2004/004726 A1

- (51) International Patent Classification7: A61K 31/47, C07D 215/38, 409/12, 401/12, 407/12, A61K 31/4709, A61P 3/04, 25/00
- (21) International Application Number:

PCT/GB2003/002884

(22) International Filing Date:

4 July 2003 (04.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0202134-3

8 July 2002 (08.07.2002) SE

- (71) Applicant (for AE. AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, I.C. LK, LR, LS, LT, LU, LY, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): ASTRAZENECA AB [SE/SE]; Sodertalje, S-151 85 (SE).
- (71) Applicant (for MG only): ASTRAZENECA UK LIM-ITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RAY, Asim, Kumar [IN/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SIGFRIDSSON, Emma, Margareta [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINUSSON, Anna, Stina, Maria [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SANDBERG, Pernilla, Marie [SF/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). INGHARDT, Tord [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SVENSSON, Anette, Marie [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). BRICKMANN, Kay [DE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).
- (74) Agent: ASTRAZENECA; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: MCHIR ANTAGONISTS

$$(R^{1})_{n} = \begin{pmatrix} (R^{2})_{m} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ \end{pmatrix}$$

(57) Abstract: The present invention provides compounds of formula (I), wherein R1 represents a C14alkoxy group optionally substituted by one or more fluoro or a C1-alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-alkyl group; L1 represents an alkylene chain (CH2), in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9, 10-methanoanthracen-9(10H)-yl the group -L1-N(R4)- together represents a piperidyl ring which is linked to L2 through the piperidinyl nitrogen and to N-R3 via the 4 position of the piperidyl ring with the proviso that when R5 represents 9, 10-methanoanthracen-9(10H)-yl then r is only 2; R4 represents H or a C1.4alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group; L² represents a bond or an alkylene chain (CH₂), in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C14alkyl group, phenyl or heteroaryl; R3 represents aryl, a heterocyclic group or a C3-8cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheier's disease and pain related disorders and to pharmaceutical compositions containing them.



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Internation No PCT/GB 03/02884

		1 1017 48 00	,					
A. CLASSIE IPC 7	FICATION OF SUBJECT MATTER A61K31/47 C07D215/38 C07D409/ A61K31/4709 A61P3/04 A61P25/0		407/12					
According to	International Patent Classification (IPC) or to both national classification	llon and IPC						
B. FIELDS	SEARCHED							
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K								
Documentat	ion searched other than minimum documentation to the extent that su	ch documents are included in the fields s	earched .					
Electronic di	ata base consulted during the international search (name of data bas	e and, where practical, search terms use	d)					
CHEM A	BS Data, EPO-Internal, WPI Data, PAJ							
	ENTS CONSIDERED TO BE RELEVANT							
Calegory *	Citation of document, with indication, where appropriate, of the rele	vani passages	Relevant to dalm No.					
X	WO 99 55677 A (SMITHKLINE BEECHAM 4 November 1999 (1999-11-04) cited in the application examples 1A,27A,29A,33B,62D	PLC, UK)	1,21					
Х	WO 97 43278 A (NOVO NORDISK A/S, DEN.;ANKERSEN, MICHAEL; STIDSEN, ENGGAARD; A) 20 November 1997 (19 example 4	21						
	_	/						
	·							
X Furl	her documents are listed in the continuation of box C.	X Patent family members are liste	d in annex.					
• Special ca	alegories of clied documents :	"T' later document published after the in	ternational filing date					
'A' document defining the general state of the art which is not clad to understand the principle or theory underlying the consistered to be of particular relevance								
"E" earlier o	document but published on or after the International late	"X" document of particular relevance; the cannot be considered novel or cannot	claimed invention					
"L" docume which challo	locument is taken atone claimed invention inventive step when the							
O docum	note other such docu- ous to a person skilled							
P docume later ti	nt family							
Date of the actual completion of the international search Date of making of the international search report								
1	7 September 2003	06/10/2003						
Name and i	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer						
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Schmid, J-C	Schmid, J-C					

Internation Mication No PCT/GB 03/02884

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Calegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 17267 A (ZYMOGENETICS, INC., USA; OSTEOSCREEN, INC.) 30 April 1998 (1998-04-30) page 5, line 29 see formula (viii) page 29, line 15 page 29, line 19 claims 37,38 figures 141,144	1,15
X	WO 99 65897 A (CHIRON CORPORATION, USA) 23 December 1999 (1999-12-23) example 12 page 1, line 8 - line 13	1-21
Χ .	US 3 020 283 A (SCHOCK, RICHARD U., JR. ET AL) 6 February 1962 (1962-02-06) cited in the application claim 1	1,15
Ρ,Χ	WO 02 058702 A (SMITHKLINE BEECHAM CORPORATION, UK) 1 August 2002 (2002-08-01) cited in the application claims; examples	1-21
P,A A .	EP 1 285 651 A (TAKEDA CHEMICAL INDUSTRIES LTD) 26 February 2003 (2003-02-26) the whole document & WO 01 082925 A 8 November 2001 (2001-11-08)	1-21
·		

Internacional application No. PCT/GB 03/02884

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 18 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos:: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Confinuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Internatio lication No PCT/GB 03/02884

Patent docu cited in searc		Publication date		Patent family member(s)	Publicati date	an
WO 99556	77 ,	A 04-11-19	99 AU BR CA CN WO EP HU JP NO PL TR US ZA	9955677 1084110 0103093	A 26-12- A1 04-11- T 08-08- A1 04-11- A1 21-03- A2 28-02- T 08-05- A 26-10- A1 27-08- T2 22-01- B1 20-11-	-2000 -1999 -2001 -1999 -2001 -2002 -2002 -2000 -2001 -2001
WO 97432		20-11-19		2764797 9743278 0912551 2001525793 6159941 6127343 9704147	A 05-12- A1 20-11- A1 06-05- T 11-12- A 12-12- A 03-10-	-1997 -1997 -1999 -2001 -2000 -2000
WO 98172	.67	30-04-19	98 AU EP JP WO US	4988997 0973513 2001510450 9817267 5948776 5965573 5990169 5939444 5922753 6017940 6153631 6342514 5919808 6251901 5994358	A1 26-01- T 31-07- A1 30-04- A 07-09- A 12-10- A 23-11- A 17-08- A 13-07- A 25-01- A 28-11- B1 29-01- A 06-07- B1 26-06-	-2000 -2001 -1998 -1999 -1999 -1999 -2000 -2000 -2002 -1999 -2001
WO 99658		A 23-12-19	P99 AU CN EP WO US US	4956699 1312807 1087963 9965897 2003130289 6417185 6489344	T 12-09- A1 04-04- A1 23-12- A1 10-07- B1 09-07-	-2001 -2001 -1999 -2003 -2002
US 30202	283	A 06-02-19	62 NONE			
WO 02058	3702	A 01-08-20	002 WO	02058702	A1 01-08	-2002
EP 12850	551	A 26-02 - 20	OO3 AU CA EP HO JP	5259601 2407149 1285651 0182925 2002241274	A1 08-11 A1 26-02 A1 08-11	-2001 -2003 -2001